Skip to main content
MHRA logo
Clinical Practice Research Datalink
UK data driving real-world evidence
  • Home
    • Senior management team
    • Job vacancies
  • News
  • Public
    • Safeguarding patient data
    • CPRD case studies
    • Approved studies
    • Data use audits
    • Data protection notice
  • Data
    • Primary care data
    • Linked data
    • Synthetic data
    • Data highlights
    • DOIs
    • Research applications
      • Data access
      • Review committees
  • Our services
    • Interventional studies
      • CPRD SPRINT
      • CPRD PROVE
    • Observational research
      • CPRD-enabled research
    • Pricing
  • General Practitioner
    • GP practice joining form
    • Quality improvement reports for GPs
    • Safeguarding patient data
    • How your data makes a difference
    • What we do with information about you
  • Research
    • Approved studies
    • Bibliography
  • Log in
    • Resource modules
      • Introduction to CPRD
      • Using CPRD primary care data
      • Using linked data
      • How to access CPRD data
      • Defining your study population
      • For MSL holders

Breadcrumb

  1. Home

Characteristics of new users of recent antidiabetic drugs in Canada and the United Kingdom

Author
V. Brunetti
A. St-Jean
S. Dell'Aniello
A. Fisher
O. H. Y. Yu
S. Bugden
J. Daigle
N. Hu
S. Alessi-Severini
B. Shah
P. Ronksley
L. Lix
P. Ernst
K. Filion
Keywords
Canada/epidemiology
Cohort Studies
*Diabetes Mellitus, Type 2/drug therapy/epidemiology
*Dipeptidyl-Peptidase IV Inhibitors/therapeutic use
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use
Glucagon-Like Peptide 1
Glucagon-Like Peptide-1 Receptor/agonists
Glucose
Humans
Hypoglycemic Agents/pharmacology/therapeutic use
Sodium
*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use
*Symporters/therapeutic use
United Kingdom/epidemiology
Type 2 diabetes
dipeptidyl peptidase 4 inhibitors
glucagon-like peptide 1 receptor agonists
sodium-glucose co-transporter 2 inhibitors
not involving SGLT-2 inhibitors or DPP-4 inhibitors.
Year of Publication
2022
Journal
BMC Endocr Disord
Volume
22
Number of Pages
241
ISBN Number
1472-6823
Accession Number
36175881
DOI
10.1186/s12902-022-01140-1
  • DOI
  • Google Scholar
  • BibTeX
  • EndNote X3 XML
  • EndNote 7 XML
  • Endnote tagged
  • Marc
  • RIS

Stethoscope

GP practices - Join today

Safety studies logo

Researcher log in

stick people holding hands

Research applications

LinkedIn
Twitter
Youtube
NIHR logo

Support links

  • Accessibility statement
  • Contact
  • Privacy notice
  • Terms and conditions
  • Login
Crown Copyright © 2023 | All Rights Reserved